This study was designed for new users of ACE inhibitors/angiotensin II receptor blockers, and used logistic regression to predict hyperkalaemia events within the first year, and demonstrated a c-index of 0.818 (95% CI 0.794–0.841) in external validation [34]. The gene discussed is ACE; the disease is Hyperkalemia.